Gilead Sciences has terminated two Phase 2 trials of its RSV antiviral candidate obeldesivir due to lower-than-expected infection rates during the recent RSV season, which impaired the ability to measure symptom reduction. Both adult and pediatric trials were ended without safety or efficacy concerns. This follows a similar cessation of a COVID-19 Phase 3 trial of obeldesivir for low incidence rates. The RSV treatment landscape is currently dominated by vaccines and prophylactic antibodies, with several companies actively developing antiviral candidates.